Jim Simons Cardiff Oncology, Inc. Call Options Transaction History
Renaissance Technologies LLC
- $63.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRDF
# of Institutions
90Shares Held
12.4MCall Options Held
813KPut Options Held
91.1K-
Black Rock Inc. New York, NY2.63MShares$8.31 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$6.86 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$2.93 Million0.0% of portfolio
-
State Street Corp Boston, MA833KShares$2.63 Million0.0% of portfolio
-
Mai Capital Management663KShares$2.1 Million0.02% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $137M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...